Max Healthcare shares rose 2% in morning trade after global brokerage Jefferies reiterated its “Buy” rating on the stock with a target price of ₹1,400. The positive sentiment stems from Max Healthcare Institute’s robust expansion plans and proven track record of execution. As of 9:51 AM, the shares were trading 1.59% higter at Rs 1,206.00.
Jefferies noted the company’s strategic goal to increase its total bed capacity by 75%—from 5,100 to 9,000 beds—within the next 3–4 years. A significant portion of this growth will come through brownfield expansion, which ensures faster breakeven timelines and enhances growth visibility.
Max Healthcare’s approach of combining brownfield projects with selective acquisitions gives it a competitive edge. Jefferies also highlighted Max’s strong operational performance in established regions like Delhi-NCR and emerging hubs like Mumbai, reinforcing confidence in its execution capabilities.
The company operates on a hub-and-spoke model and specializes in tertiary care services, including oncology, neurology, and organ transplants. This strategic setup allows it to deliver high-quality healthcare while efficiently managing patient flow between its flagship and secondary centres.
As urban healthcare demand in India continues to surge, Jefferies believes Max Healthcare is well-positioned to capitalize on the growing need for advanced medical infrastructure and quality hospital beds.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
